Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pyrovalerone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 19/20 | 1.00 |
| ▸ | SLC6A2 known ✓ | P23975 | 16/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrovalerone SCHEMBL4929129 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| Pyrovalerone SCHEMBL4930605 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| Pyrovalerone SCHEMBL121638 | 0.98 | SLC6A3 (0.97) | SLC6A3SLC6A2SLC6A4 | |
| Pyrovalerone SCHEMBL1649739 | 0.97 | SLC6A3 (0.94) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5190976 | 0.91 | SLC6A3 (0.84) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17043263 | 0.91 | SLC6A3 (0.84) | SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL15163018 | 0.90 | SLC6A3 (0.82) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4937657 | 0.88 | SLC6A3 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17043265 | 0.88 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL15162038 | 0.88 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260086062-A1 | IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2026-03-26 | — | — | US | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20230054132-A1 | DNA APTAMER-CYANINE COMPLEXES AS GENERIC COLORIMETRIC SENSORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-02-23 | — | — | US | claimed |
| US-20220323380-A1 | DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | ISANAS AG (CH) | 2022-10-13 | — | — | US | claimed |
| EP-3986391-A1 | DRUG COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | Isanas AG (CH) | 2022-04-27 | — | — | EP | claimed |
| US-11060095-B2 | Method for isolating cross-reactive aptamer and use thereof | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-07-13 | — | — | US | claimed |
| US-20210102210-A1 | METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2021-04-08 | — | — | US | claimed |
| WO-2002006826-A1 | SINGLE-PATIENT DRUG TRIALS USED WITH ACCUMULATED DATABASE | OPT-E-SCRIP, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2002000221-A1 | ENHANCED BRAIN FUNCTION BY GABA-ERGIC STIMULATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2002-01-03 | — | — | WO | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000059481-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210102210-A1 | METHOD FOR ISOLATING CROSS-REACTIVE APTAMER AND USE THEREOF | SELE, ADAR, CDA | SLC6A3 391/4885SLC6A2 380/4885SLC6A4 1014/4885 |
| US-11060095-B2 | Method for isolating cross-reactive aptamer and use thereof | SELE, ADAR, CDA | SLC6A3 391/4885SLC6A2 380/4885SLC6A4 1014/4885 |
| US-20260086062-A1 | IMMOBILIZATION STRATEGIES FOR ENHANCING SENSITIVITY OF ELECTROCHEMICAL APTAMER-BASED SENSORS | EBPL, ADA, XBP1 | SLC6A3 186/4885SLC6A2 261/4885SLC6A4 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.